{"id":"c10c3194-40c7-5e8c-868a-12113b4af18b","stable_key":"79018983-9179-5c1a-8e7a-d6f47a13582b:ki-sporo-adverse","predicate":"associated_with","statement":"Mild adverse effects occurred in 61% versus 42% (P=0.17); three patients stopped treatment because of adverse effects.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"ec0c2f66-61e0-5c25-a3c5-3bd29317c56e","mechanism_event_label":"The clinical benefit records retain the tolerability findings.","subject":{"id":"d6a7fe6a-d90e-5fad-acf4-4971b24fa8d7","slug":"potassium-iodide","display_name":"Potassium iodide","entity_type_key":"chemical_species"},"object":{"id":"a4b830dc-6e82-5928-8d89-91dd454760a1","slug":"ki-treatment-adverse-effects","display_name":"Adverse effects during potassium iodide treatment","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"ec0c2f66-61e0-5c25-a3c5-3bd29317c56e","stable_key":"79018983-9179-5c1a-8e7a-d6f47a13582b:ki-sporo-adverse-event","event_type":"observed_relationship","label":"The clinical benefit records retain the tolerability findings.","description":"Mild adverse effects occurred in 61% versus 42% (P=0.17); three patients stopped treatment because of adverse effects.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"d6a7fe6a-d90e-5fad-acf4-4971b24fa8d7","slug":"potassium-iodide","display_name":"Potassium iodide","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"a4b830dc-6e82-5928-8d89-91dd454760a1","slug":"ki-treatment-adverse-effects","display_name":"Adverse effects during potassium iodide treatment","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"Same 57-patient schedule comparison; no relapse during 45-day follow-up.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure_category","value_text":"Study-specific exposure, including pharmacological and in-vitro conditions; normal is the schema fallback outside the three availability categories.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not a long-term safety estimate or evidence about invasive sporotrichosis.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Potassium iodide research collection; shared-anion and comparator studies are not all KI interventions.","comparator":null,"unit":null,"notes":"","entity":{"slug":"potassium-iodide","display_name":"Potassium iodide","entity_type_key":"chemical_species"}},{"dimension":"plain_language","value_text":"The clinical benefit records retain the tolerability findings.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. · 1996 · https://pubmed.ncbi.nlm.nih.gov/8866807/ · DOI 10.1097/00006454-199604000-00014","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"950aae49-e47d-5d78-9277-397848cfbbb4","evidence_kind":"source_excerpt","locator":"Lines 440-446","start_line":440,"end_line":446,"excerpt":"## ki-sporo-adverse\nThe clinical benefit records retain the tolerability findings.\nMild adverse effects occurred in 61% versus 42% (P=0.17); three patients stopped treatment because of adverse effects.\nModel: Same 57-patient schedule comparison; no relapse during 45-day follow-up.\nLimitations: Not a long-term safety estimate or evidence about invasive sporotrichosis.\nEvidence location: Primary abstract\nTreatment of cutaneous sporotrichosis with one daily dose of potassium iodide. · 1996 · https://pubmed.ncbi.nlm.nih.gov/8866807/ · DOI 10.1097/00006454-199604000-00014","model_system":"Same 57-patient schedule comparison; no relapse during 45-day follow-up.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Curation paraphrase; primary evidence location and source kind retained above.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"dc3ce411-f68f-5eb8-87c1-1592665f9cb6","stable_key":"import-79018983-9179-5c1a-8e7a-d6f47a13582b","title":"Potassium iodide: thyroid and non-thyroid mechanisms, interactions and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-study references, chemical references and label statements individually identified. Not publisher full text.","file_path":"","sha256":"3ff9da818dd7a763a59c6abcff2eaee136d7f887a777034feaa5ba304a8fa6ce","revision_id":"53f2ae88-8a91-5326-ac49-3bb510ca78c3","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}